PALI-2108 — IND submission
H2 2026
IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn's disease expected in the second half of 2026Source filing
PALI biotech catalysts & pipeline
PALISADE BIO INC · Data as of 2026-09-08
Upcoming catalysts
ALTO-100 — Topline data
mid-2027
Notwithstanding, ALTO-100 is being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in mid-2027.Source filing
PALI-2108 — Topline data
H2 2027
Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027Source filing
PALI-2108 — Topline data
early 2028
Primary efficacy readout expected in early 2028Source filing
PALI-2108 — Conference presentation
Oct 9–Oct 14
Additional PALI-2108 data to be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and United European Gastroenterology (UEG) Week 2026.Source filing
PALI-2108 — Conference presentation
Oct 17–Oct 20
Additional PALI-2108 data to be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and United European Gastroenterology (UEG) Week 2026.Source filing